A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.01.025 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Jonathan Tward und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah. Electronic address: Jonathan.Tward@hci.u…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Bone Neoplasms, Radium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: We hypothesized that treatment with Radium223 (Ra223) and Stereotactic ablative radiotherapy (SABR) in patients with bone-only metachronous oligometastastic hormone-sensitive prostate cancer (moHSPC) could safely delay the start of androgen deprivation therapy (ADT) and maintain quality of life (QoL). METHODS AND MATERIALS: This prospective trial included 20 men with moHSPC and ≤5 bone-only metastases who previously had definitive treatment to the prostate and pelvic lymph nodes. Eligibility criteria were testosterone ≥ 100 ng/dL and metastases validated by conventional imaging. Exclusion criteria were postinitial treatment (LHRH) therapy or N1 disease at bone metastasis diagnosis. Treatment included 6 cycles of Ra223 and SABR (30 Gy in 5 fractions). Bone scans and Prostate Specific Antigen (PSA) levels were monitored regularly. The primary endpoint was freedom from ADT use at 15 months in ≥20% of patients. Patients were followed for 2 years, with clinically significant patient-reported outcome changes defined as >1/2 standard deviation from baseline. Statistical analyses used Wilcoxon rank sum, Pearson's χ2 tests, and univariate Cox regression, with significance set at P < .05 RESULTS: The median number of Ra223 cycles was 6. Freedom from ADT at 15 and 24 months was 50.0% and 40.0%, respectively (P < .001). Eleven (55%) and 5 (25%) patients had PSA declines exceeding 50% and 90%, respectively, with 2 patients achieving undetectable PSA levels (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah. Electronic address: Jonathan.Tward@hci.utah.edu.
- Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
- Department of Urologic Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
- Hematology and Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Zitieren
APA
Tward, J., Lloyd, S., Johnson, S., Dechet, C., Nei, B. O., Maughan, B., Swami, U., Gupta, S., Sanchez, A., Kokeny, K., & Agarwal, N. (2025). A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.01.025
Vancouver
Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, et al. A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.01.025
BibTeX
@article{Tward2025,
author = {Tward, Jonathan and Lloyd, Shane and Johnson, Skyler and Dechet, Christopher and Nei, Brock O and Maughan, Benjamin and Swami, Umang and Gupta, Sumati and Sanchez, Alejandro and Kokeny, Kristine and Agarwal, Neeraj},
title = {A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.01.025}
}
EUVIMED